LAUSR

BACKGROUND AIMS Cholestasis is characterized by intrahepatic accumulation of bile constituents, including bile acids (BAs), which promote liver damage. The apical sodium-dependent BA transporter (ASBT) plays an important role in BA reabsorption and signaling in ileum, bile ducts and kidneys. Our aim was to investigate the pharmacokinetics and pharmacological activity of A3907, an oral and systemically-available ASBT inhibitor in experimental mouse models of cholestasis. Additionally, the tolerability, pharmacokinetics, and pharmacodynamics of A3907 were examined in healthy humans. APPROACH RESULTS A3907 was a potent and selective ASBT inhibitor in vitro. In rodents, orally-administered A3907 distributed to the ASBT-expressing organs ileum, liver and kidneys, and dose-dependently increased fecal BA excretion. A3907 improved biochemical, histological and molecular markers of liver and bile duct injury in Mdr2-/- mice, and also provided direct protective effects on rat cholangiocytes exposed to cytotoxic BA concentrations in vitro. In bile-duct ligated mice, A3907 increased urinary BA elimination, reduced serum BA levels and prevented body weight loss, while improving markers of liver injury. A3907 was well-tolerated and demonstrated target engagement in healthy volunteers. Plasma exposure of A3907 in humans was within the range of systemic concentrations that achieved therapeutic efficacy in mouse.Conclusions:The systemic ASBT inhibitor A3907 improved experimental cholestatic disease by targeting ASBT function at the intestinal, liver and kidney levels, resulting in marked clearance of circulating BAs and liver protection. A3907 is well-tolerated in humans, supporting further clinical development for the treatment of cholestatic liver diseases.